Prostate Cancer Clinical Trials in Boston

Showing 61-80 of 288 trials

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

NCT06099093

The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma

Brigham and Women's Hospital30 participantsStarted Apr 2024

Boston, Massachusetts, United States • Boston, Massachusetts, United States

Active Not RecruitingPhase 2< 1 mile

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). * Docetaxel * Nivolumab

Hormone Sensitive Prostate CancerProstate AdenocarcinomaMetastasis Prostate Adenocarcinoma

Xiao X. Wei, MD60 participantsStarted May 2020

La Jolla, California, United States • Tampa, Florida, United States • Baltimore, Maryland, United States +3 more locations

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Prostate Cancer Trials in Other Cities

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

MRI Guided Prostate Biopsy

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Other Conditions in Boston